Drugs modulating adenosine receptors as potential therapeutic agents for cardiovascular diseases

Bibliography

• DRURY AN, SZENT-GYORGY A: The physiologicalactivity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. (1929) 68:213–237.
   PubMedGoogle Scholar
• VAN CALKER D, MULLER M, HAMBRECHT B: Adenosineregulates, via two different types of receptors, the accumulation of cyclic-AMP in cultured brain cells. J Neurochem. (1979) 33:999–1005.
   PubMed Web of Science ®Google Scholar
• LONDOS C, COOPER DMF, WOLFF J: Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA (1980) 77:5482–5486.
   Google Scholar
• COLLIS MG, HOURANI SMO: Adenosine receptor subtypes. Trends Pharmacol. Sci. (1993) 14:360–366.
   PubMed Web of Science ®Google Scholar
• •Useful review of adenosine receptor classification.
   Google Scholar
• DALZIEL HH, WESTFALL DP: Receptors for adenine nucleotides and nucleosides: subclassification, distri-bution and molecular characterization. Pharmacol. Rev. (1994) 46:449–466.
   PubMed Web of Science ®Google Scholar
• •Useful review of adenosine receptor classification.
   Google Scholar
• FREDHOLM BB, ABBRACCHIO MP, BURNSTOCK G et al.: Nomenclature and classification of purinocep tors. Pharmacol. Rev. (1994) 4 6 :143–156.
   Google Scholar
• •Useful review of adenosine receptor classification.
   Google Scholar
• NICHOLSON CD, SHAHID M: Inhibitors of cyclic nucleo- tide phospodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulm. Pharmacol. (1994) 7:1–17.
   PubMedGoogle Scholar
• BERNE RM: The role of adenosine in the regulation of coronary flow. Circ. Res. (1980) 47:807–813.
   PubMed Web of Science ®Google Scholar
• DRIVER AG, KUKOLY S, ALT S, MUSTAFA SJ: Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respir. Dis. (1996) 148:91–97.
   Google Scholar
• CLANACHAN AS, PARKINSON FE: Transport systems for adenosine in mammalian cell membranes. In: Purines in Cellular Signaling: Targets for New Drugs. Jacobson KA, Daly JW, Manganiello V (Eds.) Springer-Verlag, New York, USA (1990):26–32.
   Google Scholar
• SCHRADER J: Formation and metabolism of adenosineand adenine nucleotides in cardiac tissue. In: Adenosine and Adenine Nucleotides as Regulators of Cellular Function. Phyllis JW (Ed.), CRC Press, Boca Raton, Florida, USA (1990:55–69.
   Google Scholar
• BRUNS RF, LU GH, PUGSLEY GH: Characterization of theA2 adenosine receptor labelled by [311]-NECA in rat striatal membranes. Mol. Pharmacol (1996) 2 9:331–346.
   Google Scholar
• GURDEN MF, COATES J, ELLIS F et al.: Functional charac-terization of three adenosine receptor subtypes. Br. J Pharmacol. (1993) 109:693–698.
   PubMed Web of Science ®Google Scholar
• POUCHER M, KEDDIE JR, SINGH P et al.: The in vitropharmacology of ZM 341385, a potent, non-xanthine, A2 selective adenosine antagonist. Br. J Pharmacol (1995) 115:1096–1102.
   PubMed Web of Science ®Google Scholar
• ZOCCHI C, ONGINI E, CONTI A et al: The non-xanthine heterocyclic compound SCH58261 is a new potent and selective A2 adenosine receptor antagonist. J. Pharmacol. Exp. Ther. (1996) 276:398–404.
   Google Scholar
• ALEXANDER SPH, PETERS JA: 2000 Receptor and Ion channel Supplement. Trends Pharmacol. Sci. (2000)11.
   Google Scholar
• GUSTAFSSON LE, WIKLUND CU, WIKLUND NP, STELJUS L: Subclassification of neuronal adenosine receptors. In: Purines in Cellular Signalling Targets for New Drugs. Jacobson KA, Daly JW, Manganiello V (Eds.) Springer-Verlag, New York (1990):200–205.
   Google Scholar
• RIBEIRO JA, SEBASTIAO AM: Adenosine receptors and calcium; basis for proposing a third (A3) adenosine receptor. Prog. Neurobiol. (1986) 26:179–209.
   PubMed Web of Science ®Google Scholar
• ZHOU Q-Y, LI CY, OLAH ME, JOHNSON RA, STILES GL, CIVELLI O: Molecular cloning and characterization of an adenosine receptor - the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1992)89:7432–7436.
   Google Scholar
• LINDEN J: Cloned adenosine A3 receptors: pharmacol-ogical properties, species differences and receptor functions. Trends Pharmacol. Sci. (1994) 15:298–306.
   PubMed Web of Science ®Google Scholar
• ••Good review of adenosine A3 receptor pharmacology andapplications.
   Google Scholar
• CARRUTHERS AM, FOZARD JR: Adenosine A3 receptors: two into one won't go. Trends Pharmacol. Sci. (1993) 14:270–271.
   Google Scholar
• RAMKUMA RV, STILES GL, BEAVEN MA, ALT H: The A3 adenosine receptor is the unique adenosine receptor which facilitates the release of allergic mediators in mast cells. J Biol. Chem. (1993) 268:16887–16890.
   Google Scholar
• CORNFIELD LJ, HU S, HURTS D, SILLS MA: [311]-2-Phenylaminoadenosine ([3I-I-KV 1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp. Ther. (1992) 263:552–561.
   PubMed Web of Science ®Google Scholar
• BROADLEY KJ: Purines In: Airways Smooth Muscle: Neurotransmitters, Amines, Lipid Mediators and Signal Transduction. Raeburn D, Giembycz MA (Eds.), Birkhauser-Verlag, Basel (1995):271–307.
   Google Scholar
• POLOSA R, HOLGATE ST: Adenosine provocation: a promising marker of allergic inflammation in asthma? Thorax (1997) 52:919–923.
   PubMed Web of Science ®Google Scholar
• THORNE JR, DANAHAY H, BROADLEY KJ: Analysis of the bronchoconstrictor responses to adenosine receptor agonists in sensitized guinea-pigs. Eur. J. Pharmacol (1996) 316:263–271.
   Google Scholar
• FEOKTISTOV I, BIAGGIONNI I: Pharmacological charac-terization of adenosine A2B receptors: studies in human mast calls co-expressing A2A and A2B adenosine receptor-subtypes. Biochem. Pharamacol. (1998) 55:627–633.
   PubMed Web of Science ®Google Scholar
• RAMKUMAR V, NIE Z, RYBAK LP, MAGGIRWAR SB: Adenosine, antioxidant enzymes and cytoprotection. Trends Pharmacol. Sci. (1995) 16:283–285.
   Google Scholar
• ••Review of adenosine actions on inflammatory cells
   Google Scholar
• JORDAN JE, ZHAO Z-Q, SAT H, TAFT S, VINTEN-JOHANSEN J: Adenosine A2 receptor activation attenu-ates reper fusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelium adherence./ Pharmacol. Exp. Ther. (1997) 280:301–309.
   Google Scholar
• WALKER BAM, JACOBSON MA, KNIGHT DA et al.: Adenosine A3 receptor expression and function in eosinophils. Am. Rev. Respir. Cell Mol. Biol. (1997) 1 6:531–537.
   Google Scholar
• British National Formulary, British Medical Associa-tion/Royal Pharmaceutical Society of Great Britain, London. (1999) 37:69.
   Google Scholar
• SYLVEN C: Mechanisms of pain in angina pectoris - a critical review of the adenosine hypothesis. Cardio-vasc. Drugs Ther. (1993) 7:745–759.
   Google Scholar
• MURAD F: Drugs used for the treatment of angina: Organic nitrates, calcium-channel blockers and _-adrenergic antagonists. In: Goodman and Gilman 's The Pharmacological Basis of Therapeutics (8th Edition). Gilman AG, Rall TVV, Nies AS, Taylor P (Eds.), Pergamon Press, New York, USA (1990764–783.
   Google Scholar
• POUCHER SM: The role of the A2A adenosine receptor subtype in functional hyperaemia in the hind limb of anaesthetized cats. J. Physiol (1996) 492 (Part 2)495–503.
   Google Scholar
• POUCHER SM: Ischaemic skeletal muscle hyperaemia in the anaesthetized cat: no contribution of A2A adenosine receptors. J Physiol. (1997) 500:205–212.
   Google Scholar
• OLSSON RA, PEARSON JD: Cardiovascular purinocep-tor s. Physic)]. Rev. (1990) 70:761–845.
   PubMed Web of Science ®Google Scholar
• •Still a useful review of the cardiovascular effects and receptor classification of adenosine.
   Google Scholar
• BOWMER CJ, YATES MS: Therapeutic potential for new selective adenosine receptor ligands and metabolism inhibitors. Trends Pharmacol. Sci. (1989) 10:339–341.
   Google Scholar
• •Useful review of therapeutic applications of adenosine receptor agonists/antagonists.
   Google Scholar
• NOOTENS M, SCHRADER B, KAUFMANN E, VESTAL R, LONG W, RICH S: Comparative effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest (1995) 107:54–57.
   Google Scholar
• NEELY CF, HAILE DM, CAHILL BE, KADOWITZ PJ: Adenosine and ATP produce vasoconstriction in the feline pulmonary vascular bed by different mechanisms. J. Pharmacol Exp. Ther. (1991) 258:753–761.
   Google Scholar
• BROADLEY KJ, MADDOCK HL: Pi-purinoceptor-mediated vasodilatation and vasoconstriction in hypoxia. J. Auton. Pharmacol (1996) 16:363–366.
   Google Scholar
• MUBAGWA K, MULLANE K, FLAMENG W: Role of adenosine in the heart and circulation. Cardiovasc. Res. (1996) 32:797–813.
   PubMed Web of Science ®Google Scholar
• •Good general review of the cardiovascular effects of adenosine and therapeutic applications.
   Google Scholar
• LIANG BT, SWIERKOSZ TA, HERRMANN HC, KIMMEL S, JACOBSON KA: Adenosine and ischaemic precondi-tioning. Curr. Pharm. Design (1999) 5:1029–1041.
   Google Scholar
• BOACHIE-ANSAH G, KANE KA, PARRATT JR: Is adenosine an endogenous myocardial protective (antiar-rhythmic) substance under conditions of ischaemia? Cardiovasc. Res. (1993) 27:77–83.
   Google Scholar
• McCLANAHAN TB, IGNASIAK DP, MARTIN BJ, MERTZ TE, GALLAGHER KP: Effect of adenosine deaminase inhibi-tion with pentostatin on myocardial stunning in dogs. Basic Res. Cardiol. (1995) 9:176–183.
   Google Scholar
• ABD-ELFATTAH AS, DING M, DYKE CM, WECHSLER AS: Protection of the stunned myocardium. Selective nucleoside transport blocker administered after 20 minutes of ischemia augments recovery of ventricular function. Circulation (1993) 88:11336–11343.
   Google Scholar
• RANDHAWA MP, LASLEY RD, MENTZER RM, JR.: Adenosine and the stunned heart. J. Card. Surg. (1993) 8 (Suppl. 2):332–337.
   Google Scholar
• RANDHAWA MP, LASLEY RD, MENTZER RM, JR.: Salutary effects of exogenous adenosine administration on in vivo myocardial stunning. J. Thoracic Cardiovasc. Surg. (1995) 10:63–74.
   Google Scholar
• OGAWA T, MIURA T, SHIMAMATO K, IIMURA O: Activa-tion of adenosine receptors before ischemia enhances tolerance against myocardial stunning in the rabbit heart. J Am. Coll. Cardiol. (1996) 27:225–233.
   Google Scholar
• LASLEY RD, MENTZER RM: Protective effects of adenosine in the reversibly injured heart. Ann. Thoracic Surg. (1995) 60:843–846.
   Google Scholar
• HEUSCH G: Myocardial stunning: a role for calcium antagonists during ischaemia? Cardiovasc. Res. (1992) 26:14–19.
   Google Scholar
• SCHULZ R, EHRING T, HEUSCH G: Stunned myocar-dium: inotropic reserve and pharmacological attenua-tion. Basic Res. Cardiol (1995) 90:294–296.
   Google Scholar
• LASLEY RD, MENTZER RM: Adenosine increases lactate release and delays onset of contracture during global low flow ischaemia. Cardiovasc. Res. (1993) 27:96–101.
   Google Scholar
• LASLEY RD, RHEE JVV, VAN WYLEN DGL, MENTZER RM: Adenosine Ai receptor mediated protection of the globally ischemic isolated rat heart. J Mol. Cell. Cardiol (1990) 22:39–47.
   Google Scholar
• GARDNER NM, BROADLEY KJ: Hypoxia-induced stunning in isolated cardiac tissues: the effect of an A3 receptor agonist. Br. J. Pharmacol. (1997) 120:179P.
   Google Scholar
• GARDNER NM, BROADLEY KJ: Role of endogenous adenosine and A3 receptor stimulation in hypoxia-induced myocardial stunning and contracture. Br. J Pharmacol. (1998) 123:279P.
   Google Scholar
• THOURANI VH, NAKAMURA M, RONSON RS et al.: Adenosine A3-recep tor stimulation attenuates p ostischemic dysfunction through K(ATP) channels. Am. J. Physic)]. (1999) 277:H228–H235.
   Google Scholar
• THOURANI VH, RONSON RS, JORDAN JE, GUYTON RA,VINTEN-JOHANSEN J: Adenosine A3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. Ann. Thorac. Surg. (1999) 67:1732–1737.
   Google Scholar
• MADDOCK H, BRIL A, BROADLEY K, KHANDOUDI N: Adenosine-induced protection is mediated by A2, receptor activation. Groupe de Reflexion sur la Recherche Cardio-vasculaire, Lyon (1996):Abstract 9–6.
   Google Scholar
• AUCHAMPACH JA, RIZVI A, QIU Y et al.: Selective activa-tion of A3 adenosine receptors with N6-(3-iodobenzyl) adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemody-namic changes in conscious rabbits. Circ. Res. (1997) 80:800–809.
   PubMed Web of Science ®Google Scholar
• ELY SW, BERNE RM: Protective effects of adenosine inmyocardial ischemia. Circulation (1992) 85:893–904.
   PubMed Web of Science ®Google Scholar
• FRALIX TA, MURPHY E, LONDON RE, STEENBERGEN C:Protective effects of adenosine in the perfused rat heart - changes in metabolism and intracellular ion homeostasis. Am. J Physiol (1993) 264:C986–C994.
   Google Scholar
• THORNTON JD, LIU GS, OLSSON RA, DOWNEY JM: Intravenous pretreatment with Ai-selective adenosine analogs protects the heart against infarction. Circula-tion (1992) 85:659–665.
   PubMed Web of Science ®Google Scholar
• TOOMBS CF, MCGEE DS, JOHNSON WE, VINTEN JOHANSEN J: Myocardial protective effects of adenosine-infarct size reduction with pretreatment and continued receptor stimulation duringischaemia. Circulation (199?) 86:986–994.
   Google Scholar
• ZHAO ZQ, NAKANISHI K, MCGEE DS, TAN P, VINTEN-JOHANSEN J: Ai Receptor-mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc. Res. (1992) 28:270–279.
   Google Scholar
• JORDAN JE, ZHAO Z-Q, SATO H, TAFT S, VINTEN-JOHANSEN J: Adenosine A2 receptor activation attenu-ates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. (1997) 280:301–309.
   Google Scholar
• HORI M, KITAKAZE, M, TAKASHIMA S: Beneficial role ofadenosine in myocardial ischaemic and reperfusion injury. Drug Develop. Res. (1993) 28:432–437.
   Web of Science ®Google Scholar
• PARRATT JR: Protection of the heart by ischaemicpreconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol. ScL (1994) 15:19–25.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG S, GANOTE CE: Adenosine receptor specificity in preconditioning of isolated cardiomyo-cytes: evidence of A3 receptor involvement. Cardiovasc. Res. (1994) 28:1049–1056.
   PubMed Web of Science ®Google Scholar
• LIU GS, THORNTON J, VAN WINKLE DM, STANLET AWH,OLSSON RA, DOWNEY JM: Protection against infarction afforded by preconditioning is mediated by Ai-adenosine receptors in rabbit heart. Circulation (1991) 84:350–356.
   PubMed Web of Science ®Google Scholar
• YELLON DM: Preconditioning the myocardium:experimental and clinical perspectives. Br. J Cardiol. (1995) 39–42.
   Google Scholar
• PARRATT JR, SZEKERES L: Delayed protection of theheart against ischaemia. Trends Pharmacol. ScL (1995) 16 :351–355.
   PubMedGoogle Scholar
• ASIMAKIS GK, INNERS-MCBRIDE K, CONTI VR: Attenua-tion of postischaemic dysfunction by ischaemic preconditioning is not mediated by adenosine in the isolated rat heart. Cardiovasc. Res. (1993) 27:1522–1530.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA A, LIU GS, WILBORN WH, DOWNEY JM: Pretreatment with the adenosine Ai selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in rabbits. Cardio-vasc. Res. (1993) 27:652–656.
   PubMed Web of Science ®Google Scholar
• HALE SL, BELLOWS SD, HAMMERMAN H, KLONER R: Anadenosine Ai receptor agonist, R(-)-N-(2-phenyl isopropyl)-adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits. Cardiovasc. Res. (1993) 27:2140–2145.
   PubMed Web of Science ®Google Scholar
• LIU GS, RICHARDS SC, OLSSON RA, MULLANE K, WALSH RS, DOWNEY JM: Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardio-vasc. Res. (1994) 28:1057–1061.
   PubMed Web of Science ®Google Scholar
• GROSS GJ, AUCHAMPACH JA: Blockade of ATP-sensitive potassium channels prevents myocardial recondi-tioning in dogs. Circ Res. (1992) 70:223–233.
   PubMed Web of Science ®Google Scholar
• SPEECHLY-DICK M, MOCANU M, YELLON D: Protein kinase C. Its role in ischaemic preconditioning in the rat. Circ. Res. (1994) 75:586–590.
   Google Scholar
• MULLANE K: Acadesine; the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc. Res. (1993) 27:43–47.
   PubMed Web of Science ®Google Scholar
• HORI M, KITAKAZE M, TAKASHIMA S et al.: AICAriboside improves myocardial ischemia in coronary microem-bolization in dogs. Am. J Physiol (1994) 267:H1483–H1495.
   Google Scholar
• TSUCHIDA A, LIU GS, MULLANE K, DOWNEY JM: Acadesine lowers temporal threshold for the myocar-dial infarct size limiting effect of preconditioning. Cardiovas. Res. (1993) 27:116–120.
   PubMedGoogle Scholar
• LEUNG J, STANLEY T, MATHEW J et al.: Effects of acadesine on perioperative cardiac morbidity in a placebo-controlled, double-blind study. J. Am. Coll. Cardiol. (1992) 19:112A.
   Google Scholar
• LASLEY RD, RANDHAWA MP, JR., HEGGE JO, MENTZER RM, JR.: Effects of adenosine and acadesine on intersti-tial nucleosides and myocardial stunning in the pig. Can. J. Physic)]. Pharmacol. (1999) 77:259–267.
   Google Scholar
• DE JONG R, MACLEOD DC, SURYAPRANATA H: Effect of acadesine on myocardial ischaemia in patients with coronary artery disease. Eur. J Pharmacol. (1997) 337:41–44.
   Google Scholar
• MENASCHE P, JAMIESON WR, FLAMENG W, DAVIES MK:Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Result of the first international multicentre study. Multina-tional adadesione study group. J. Thorac. Cardiovasc. Surg. (1995) 110:1096–1106.
   Google Scholar
• MANGANO DT: Effects of acadesine on myocardial infarction, stroke and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter study of Perioperative Ischemia (McSPI) Research Group. JAMA (1997) 277:22–29.
   Google Scholar
• ZIVAN JA, CHOI DW: Stroke therapy Scientific American (1991) 265:56–63.
   Google Scholar
• SIESJO BK: Mechanisms of ischemic brain damage. Grit. Care Med. (1988) 16:954.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, MORI Y: Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Eur. J. Pharmacol. (1998) 363:1–15.
   PubMed Web of Science ®Google Scholar
• RUDOLPHI KA, SCHUBERT P, PARKINSON FE, FREDHOLM BB: Neuroprotective role of adenosine in cerebral ishaemia. Trends Pharmacol Sci. (1992) 13:439–445.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA: Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. (1998) 1 9:184–191.
   Google Scholar
• ••Very useful review of A3 receptor pharmacology andtherapeutic applications.
   Google Scholar
• ABBRACCHIO MP, CERUTI S, BRAMBILLA R et al.: Modula-tion of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann. NY Acad. Sci. (1997) 825:11–22.
   Google Scholar
• VON LUBITZ DK, LIN RC, POPIK P, CARTER MF, JACOBSON KA: Adenosine A3 receptor stimulation and cerebral ischemia. Eur. j Pharmacol (1994) 263:59–67.
   PubMed Web of Science ®Google Scholar
• KITAKAZE M, HORI M, SATO H et al.: Endogenous adenosine inhibits platelet aggregation during myocardial, ischemia in dogs. Circ. Res. (1991) 69:1402–1408.
   PubMed Web of Science ®Google Scholar
• ADAIR TH, GAY WJ, MONTANI J-P: Growth regulation of the vascular system: evidence for a metabolic hypothesis. Am. J Physiol (1990) 259:R393–R404.
   PubMed Web of Science ®Google Scholar
• MEININGER CJ, SCHELLING ME, GRANGER HJ: Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am. J Physiol. (1988) 255:H554–H562.
   Google Scholar
• YAO Y, SEI Y, ABBRACCHIO MP, JIANG J-L, KIM Y-C, JACOBSON KA: Adenosine A3 receptor agonists protect 1-1L-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem. Biophys. Res. Comm. (1997) 232:317–322.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, MORO S, KIM Y-C, LI A-H: A3 adenosine receptors: protective vs. damaging effects identified using novel agonists and antagonists. Drug Dev. Res. (1998) 45:113–124.
   Google Scholar
• MAGGIRWAR SB, DHANRAJ DN, SOMANI SM, RAMKUMAR V: Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem. Biophys. Res. Comm. (1994) 201:508–515.
   PubMed Web of Science ®Google Scholar
• SEI Y, VON LUBITZ DKJE, ABBRACCHIO MP, JI X, JACOBSON KA: Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Dev. Res. (1997) 40:267–273.
   Web of Science ®Google Scholar
• CHOW SC, KASS GEN, ORRENIUS S: Purines and their role in apoptosis. Neuropharmacology. (1997) 36 :1149–1156.
   Google Scholar
• JACOBSON KA, HOFFMANN C, CATTABENI F, ABBRAC-CHIO MP: Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis (1999) 4:197–211.
   PubMed Web of Science ®Google Scholar
• MULLER CE, SAUER R, MAURINSH Y et al: A2A-selective adenosine receptor antagonists: development of water-soluble prodrugs and a new tritiated radioligand. Drug Dev. Res. (1998) 45:190–197.
   Google Scholar
• FEOKTISTOV I, POLOSA R, HOLGATE ST, BIAGGIONI I: Adenosine A2 B receptors: a novel therapeutic target in asthma. Trends Pharmacol Sci. (1998) 19:148–153.
   PubMed Web of Science ®Google Scholar
• •Probably the only review of A2B receptor pharmacology and applications, although principally on airways applications.
   Google Scholar
• EZEAMUZIE CI, PHILIPS E: Adenosine A3 receptors on human eosinophils mediate inhibition of degranula-tion and superoxide anion generation. Br.J Pharmacol (1999) 127:188–194.
   PubMed Web of Science ®Google Scholar
• HO AD, SUCIU S, STRYCKMANS P et al: Pentostatin in T-cell malignancies - a Phase II trial of the EORTC. Ann. Oncol (1999) 10:1493–1498.
   PubMed Web of Science ®Google Scholar
• KREITMAN RT, CHESON BD: Treatment of hairy cell leukemia at the close of the 20th century. Hematology (1999) 4:283–303.
   PubMedGoogle Scholar
• TALLMAN MS, PETERSON LC, HAKIMIAN D, GILLIS S, POLLIACK A: Treatment of hairy-cell leukemia: current views. Semin. Hematol (1999) 36:155–163.
   PubMed Web of Science ®Google Scholar
• BROGDEN RN, SORKIN EM: Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in lymphoproliferative disorders. Drugs (1993) 46:652–677.
   Google Scholar
• BELARDINELLI L: Adenosine system in the heart. Drug Dev. Res. (1993) 28:263–267.
   Google Scholar